Document Type

Patent

Publication Date

July 2014

Patent Number

8778986

CPC

C07D 311/30(20130101), A61K 31/352(20130101)

Abstract

The bioflavonoid luteolin reduces amyloid-β peptide (Aβ) generation. Luteolin is also a selective GSK-3 inhibitor that 1) decreases amyloidogenic γ-secretase APP processing, and 2) promotes presenilin-1 (PS1) carboxyl-terminal fragment (CTF) phosphorylation. GSK-3α activity is essential for both PS1 CTF phosphorylation states and PS1-APP interaction. To validate The findings were validated in vivo, using a Tg2576 Alzheimer's Disease model system. Luteolin treatment decreased soluble Aβ levels, reduced GSK-3 activity, and disrupted PS1-APP association.

Application Number

12/020,214

Assignees

University of South Florida

Filing Date

01/25/2008

Primary/U.S. Class

514/456

Share

COinS